HCW Biologics (HCWB) Non-Current Assets (2020 - 2025)
HCW Biologics' (HCWB) quarterly Non-Current Assets came in at $22.2 million in Q4 2025, down 9.38% YoY from $24.5 million in Q4 2024, and down 6.8% on a QoQ basis from $23.9 million in Q3 2025.
HCW Biologics (HCWB) Non-Current Assets (2020 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 6 years of Non-Current Assets data on file, last reported at $22.2 million in Q4 2025.
- Quarterly Non-Current Assets fell 9.38% year-over-year to $22.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96.5 million (down 1.19% YoY) and the FY2025 annual result came in at $22.2 million, down 9.38% from the prior year.
- Non-Current Assets fell to $22.2 million in Q4 2025, from $23.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $26.0 million in Q2 2025 to a low of $3.0 million in Q2 2021.
- A 5-year average of $19.0 million and a median of $22.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 327.85% — and 2025, when it fell 9.38%.
- Tracing HCWB's Non-Current Assets over 5 years: stood at $13.0 million in 2021, then declined by 2.27% to $12.7 million in 2022, then soared by 73.57% to $22.1 million in 2023, then increased by 10.98% to $24.5 million in 2024, then dropped by 9.38% to $22.2 million in 2025.
- The last three Non-Current Assets figures came in at $22.2 million (Q4 2025), $23.9 million (Q3 2025), and $26.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | 25.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.24 Mn |
| Sep 30, 2025 | 23.86 Mn |
| Jun 30, 2025 | 26.01 Mn |
| Mar 31, 2025 | 24.39 Mn |
| Dec 31, 2024 | 24.54 Mn |
| Sep 30, 2024 | 24.46 Mn |
| Jun 30, 2024 | 24.43 Mn |
| Mar 31, 2024 | 24.22 Mn |
| Dec 31, 2023 | 22.11 Mn |
| Sep 30, 2023 | 21.77 Mn |
| Jun 30, 2023 | 19.68 Mn |
| Mar 31, 2023 | 13.59 Mn |
| Dec 31, 2022 | 12.74 Mn |
| Sep 30, 2022 | 22.65 Mn |
| Jun 30, 2022 | 12.78 Mn |
| Mar 31, 2022 | 13.05 Mn |
| Dec 31, 2021 | 13.03 Mn |
| Sep 30, 2021 | 12.85 Mn |
| Jun 30, 2021 | 2.99 Mn |
| Dec 31, 2020 | 3.25 Mn |